Babesiosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Babesiosis Market Outlook

Thelansis’s “Babesiosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Babesiosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Babesiosis Overview

Babesiosis is an infection of parasitic nature instigated by protozoa belonging to the genus Babesia. The species of Babesia have been categorized into four distinct clades. Babesia microti, classified as a Clade 1 organism, is the most prevalent and comprehensively described species. The primary mode of acquiring Babesiosis is through tick bites carrying the protozoa. Given that the parasite infects erythrocytes (red blood cells), the infection can also be contracted through blood transfusion, thereby affecting individuals not exposed to endemic areas. Babesia predominantly infects red blood cells, often appearing oval or pear-shaped. The ring form and peripheral location in the red blood cell can lead to misinterpretation of the smear for Plasmodium falciparum. However, unlike Plasmodium, hemolysis is rare in Babesiosis. The increased aggregation and rigidity of the red blood cells often result in acute respiratory distress and noncardiogenic pulmonary edema. Fragmentation of red blood cells can also lead to capillary blockage in various organs. The spleen, responsible for trapping damaged red cells, can become enlarged. Patients lacking a spleen tend to experience a more severe disease course. Asymptomatic Babesia infection may persist subclinically for months to years in otherwise healthy individuals, particularly those under 40. Symptomatic Babesiosis typically commences after a 1- to 2-week incubation period with nonspecific symptoms, including myalgia, headache, fever, chills, fatigue, malaise, and arthralgia. In healthy individuals, symptoms usually resolve after a week. In others, hepatosplenomegaly may occur with mild neutropenia, mild to moderately severe hemolytic anemia, jaundice, and thrombocytopenia. Noncardiac pulmonary edema can develop in severe disease. Asymptomatic patients usually do not require treatment, but therapy is indicated for patients with persistent high fever, rapidly increasing parasitemia, and falling hematocrit. The combination of atovaquone and azithromycin administered for 7 to 10 days has fewer adverse effects. It is as effective as traditional therapy with quinine plus clindamycin in patients with mild to moderate Babesiosis. The adult dosage is atovaquone 750 mg orally every 12 hours and azithromycin 500 to 1000 mg on the first day, followed by a daily dose of 250 to 1000 mg. In children weighing over 5 kg, the dosage is atovaquone 20 mg/kg orally twice a day plus azithromycin 10 mg/kg once, then 5 mg/kg daily for 7 to 10 days. Quinine 650 mg orally three times a day plus clindamycin 600 mg orally three times a day or 300 to 600 mg IV four times a day for 7 to 10 days can also be used. The pediatric dosage is quinine 10 mg/kg orally three times a day plus clindamycin 7 to 14 mg/kg three times daily. Quinine plus clindamycin is considered the standard of care for severely ill patients. Recipients of quinine must be monitored closely for adverse effects. In patients suffering from severe illness with high parasitemia (more than 10% of erythrocytes), exchange transfusion has been employed as a treatment method. The future health condition of Babesiosis patients is largely dependent on the nature of their symptoms. A majority of patients exhibit no symptoms and generally have a favorable prognosis. Some may experience an infection similar to the flu, which typically results in a positive outcome. However, patients with severe forms of the disease may face a lengthy recovery period marked by multiorgan dysfunction and, in some cases, death. This is particularly common in patients who do not have a spleen. Symptoms of Babesiosis can persist for 6-8 weeks, while patients without symptoms may go undiagnosed for several years. It is recommended that all patients who test positive for the disease three months after initial treatment undergo another round of treatment, regardless of whether they have experienced seizures. Approximately one-fifth of patients with Babesiosis may be co-infected with Lyme disease. These patients tend to have a more prolonged course.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: